Hydroxychloroquine mechanism of action lupus

Discussion in 'Canadian Pharmacy Drugs Online' started by sonar, 05-Mar-2020.

  1. Kittens killer New Member

    Hydroxychloroquine mechanism of action lupus


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Experimental chloroquine treatment marines haiti Concurrent administration of chloroquine Hydroxychloroquine lung cancer Liquid plaquenil

    The mechanisms of action of HCQ, and clinical and experimental data in systemic lupus erythematosus SLE and APS are discussed. As HCQ reduces the risk of thrombosis in both SLE patients and animal models of APS 1–7, and possibly decreases the titre of aPL 8, its beneficial role as a potential antithrombotic could be suggested. Hydroxychloroquine Sulfate Drug Information from Includes Hydroxychloroquine Sulfate side effects, interactions and indications. lupus erythematosus suppressant—. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit 1989; 114 369-79. Hydroxychloroquine in systemic lupus erythematosus SLE. In this review the mechanisms of action, the efficacy, and the safety of HCQ in the management of patients with SLE have been reviewed.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine mechanism of action lupus

    Hydroxychloroquine An old drug with new relevance., Hydroxychloroquine Sulfate Drug Information, Professional

  2. Aralen for lupus
  3. Hydroxychloroquine HCQ belongs to the group of antimalarial agents, which recognition of its benefit in other diseases except malaria dates back to 1894, when Payne reported that quinine was effective in cutaneous lupus. Since then, therapeutic effects of antimalarial agents were shown in a myriad of other diseases and the evidence for its potential benefit continues to grow.

    • Hydroxychloroquine From Malaria to Autoimmunity..
    • Hydroxychloroquine in systemic lupus erythematosus SLE.
    • Antimalarials in systemic lupus erythematosus benefits..

    Mechanism of action of hydroxychloroquine as an antirheumatic drug. Fox RI1. Author information 1Department of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, CA 92037. The antimalarial agents chloroquine and hydroxychloroquine have been used widely for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Chloroquine and hydroxychloroquine are drugs derived from the quinoline molecule. Both are used as antimalarial blood schizonticides, and hydroxychloroquine is also frequently used as an antirheumatic. Their mechanism of action is not entirely understood. Hydroxychloroquine HCQ is an antimalarial agent that has been used in systemic lupus erythematosus SLE and rheumatoid arthritis RA treatments for many years. Recently, advances in our understanding of its mechanisms of action have expanded the therapeutic prospects of HCQ 1–3.

     
  4. Natulya Guest

    Description: An exception occurred while processing your request. Plaquenil Eye Exams - Catalina Eye Care Plaquenil Risk Calculators Plaquenil therapy and eye exams. - Eye Care - MedHelp
     
  5. Luerssen User

    The Risk of Retinal Toxicity with Plaquenil - Sjogren's The side effect that is of greatest concern is retinal toxicity. Retinal toxicity of Plaquenil may manifest itself with subtle disturbances of the retinal pigment epithelium which may eventually lead to complete destruction of the macula in the form of bull’s-eye maculopathy.

    Early Plaquenil Toxicity Detected without Bull’s Eye Maculopathy
     
  6. moby-dick Guest

    Plaquenil vs. Aralen Prescription Treatment for Malaria. Plaquenil hydroxychloroquine and Aralen chloroquine phosphate are antimalarial medications used to treat or prevent malaria, a disease caused by parasites, which enter the body through the bite of a mosquito. Plaquenil is also used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Aralen is also used to treat infections caused by amoebae.

    White Spots On Fish - Chloroquine Phosphate To Treat Parasites